Abstract 3594
Background
We conducted NGS of baseline UC tumors to elucidate molecular predictors of clinical outcomes on D/D+T.
Methods
CP1108/NCT01693562 was a nonrandomized phase I/II trial including 201 2L UC pts who were treated with D (10 mg/kg Q2W). Study 10/NCT02261220 was a phase I trial including 190 2L UC pts treated with D (20 mg/kg Q4W) +T (1 mg/kg Q4W). Pts with ≥25% PD-L1 expression in tumor or immune cells were scored as PD-L1+ by IHC. RNA-seq (n = 62) and whole exome sequencing (WES; n = 37) were used in CP1108. The IFN-γ gene signature (IFNGS) was calculated as described (Higgs B et al., 2018). TMB was calculated as somatic coding mutation count per mega base from WES data with TMB≥top tertile as TMB high. FMI assay (n = 62) was conducted in Study 10 with TMB≥top tertile as TMB high. ctDNA dynamics using Guardant360 were calculated using an established method (Raja R, et al., 2018). Wilcoxon, log-rank tests and COX-PH model were used in relevant statistical tests.
Results
Among ITT pts, 55% and 44.5% pts were PD-L1+ in CP1108 and Study 10 respectively. PD-L1 status correlated with IFNGS (p < 0.001), whereas PD-L1 did not correlate with TMB. PD-L1+ correlated with better OS in CP1108 (HR = 0.46, p < 0.001) but not in Study 10 (HR = 0.75, p = 0.2). IFNGS significantly correlated with better PFS in CP1108 (HR = 0.5, p = 0.02). Higher TMB in CP1108 using the median cutoff trended towards better OS (HR = 0.51, p = 0.18), but no clear trend using the top tertile cutoff due to small sample size. Higher TMB in Study 10 correlated with improved OS (HR = 0.34, p = 0.01). In Study 10, TMB and PD-L1 double positive pts (n = 14, 24%) had best OS and pts low in both had worst (n = 19, 32%, HR = 0.23, p = 0.01). Clearance of ctDNA after treatment correlated with better OS (HR = 0.23, p = 0.006) and PFS (HR = 0.33, p = 0.01) in combined UC pts from the 2 studies.
Conclusions
Both PD-L1 and TMB predict for survival benefit in UC pts treated with D/D+T. They identify overlapping but generally distinct patient populations. Double highs perform the best. ctDNA loss following treatment can be predictive for better survival.
Clinical trial identification
NCT01693562; NCT02261220.
Editorial acknowledgement
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
C. Massard: Advisory / Consultancy: Amgen; Advisory / Consultancy: Astellas; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy: Celgene; Advisory / Consultancy: Genentech; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Novartis; Advisory / Consultancy: Roche; Speaker Bureau / Expert testimony: Sanofi; Advisory / Consultancy: Janssen; Advisory / Consultancy: Lilly; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Orion. H. Si: Full / Part-time employment: AstraZeneca. Q. Zhang: Full / Part-time employment: AstraZeneca. B. Higgs: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. R. Raja: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. S.E. Abdullah: Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. A. Gupta: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca; Shareholder / Stockholder / Stock options, Licensing / Royalties, Use of immunotherapy in the treatment of cancer-patent: Bristol-Myers Squibb. W. Li: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. M. van der Heijden: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy: MSD; Advisory / Consultancy, Research grant / Funding (institution): Roche/Genentech; Advisory / Consultancy, Research grant / Funding (institution): Astellas; Advisory / Consultancy: Seattle Genetics.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract